1. Home
  2. PAVM vs SCYX Comparison

PAVM vs SCYX Comparison

Compare PAVM & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PAVmed Inc.

PAVM

PAVmed Inc.

HOLD

Current Price

$5.11

Market Cap

43.1M

Sector

Health Care

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$5.23

Market Cap

37.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAVM
SCYX
Founded
2014
1999
Country
United States
United States
Employees
41
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.1M
37.0M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
PAVM
SCYX
Price
$5.11
$5.23
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$65.00
$3.00
AVG Volume (30 Days)
8.6K
231.6K
Earning Date
05-15-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.36
EPS
N/A
N/A
Revenue
N/A
$257,000.00
Revenue This Year
$603.94
N/A
Revenue Next Year
$33.16
$608.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.21
$0.57
52 Week High
$28.44
$5.62

Technical Indicators

Market Signals
Indicator
PAVM
SCYX
Relative Strength Index (RSI) 44.60 65.23
Support Level $4.45 $0.65
Resistance Level $6.56 $5.62
Average True Range (ATR) 0.46 0.45
MACD -0.01 0.11
Stochastic Oscillator 37.46 83.08

Price Performance

Historical Comparison
PAVM
SCYX

About PAVM PAVmed Inc.

PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: